Lilly Moves Into Migraine Race With CHMP Okay

Competition is hotting up in the CGRP class of new migraine therapies, with Lilly's Emgality being recommended for approval in Europe, paving the way for a market share battle with Novartis' Aimovig.

Balloons
Emgality is close behind Aimovig en route to European migraine market • Source: Shutterstock

Having secured a recommendation for approval in Europe for Emgality (galcanezumab,) and with a green light expected this week from the FDA, Eli Lilly has now caught up with Amgen Inc., Novartis AG and Teva Pharmaceutical Industries Ltd. and their respective calcitonin gene-related peptide (CGRP) blockers for the prevention of migraine.

Emgality is almost certain to be approved in Europe in the next couple of months after the European Medicines Agency's...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from New Products

More from Scrip